GYRE
Price
$6.43
Change
-$1.29 (-16.71%)
Updated
Apr 1, 04:59 PM (EDT)
Capitalization
600.06M
36 days until earnings call
PYXS
Price
$0.91
Change
-$0.07 (-7.14%)
Updated
Apr 1, 04:59 PM (EDT)
Capitalization
60.65M
37 days until earnings call
Ad is loading...

GYRE vs PYXS

Header iconGYRE vs PYXS Comparison
Open Charts GYRE vs PYXSBanner chart's image
Gyre Therapeutics
Price$6.43
Change-$1.29 (-16.71%)
Volume$9.78K
Capitalization600.06M
Pyxis Oncology
Price$0.91
Change-$0.07 (-7.14%)
Volume$5.26K
Capitalization60.65M
GYRE vs PYXS Comparison Chart
Loading...
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PYXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GYRE vs. PYXS commentary
Apr 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GYRE is a StrongBuy and PYXS is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 02, 2025
Stock price -- (GYRE: $7.72 vs. PYXS: $0.98)
Brand notoriety: GYRE and PYXS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GYRE: 312% vs. PYXS: 116%
Market capitalization -- GYRE: $600.06M vs. PYXS: $60.65M
GYRE [@Biotechnology] is valued at $600.06M. PYXS’s [@Biotechnology] market capitalization is $60.65M. The market cap for tickers in the [@Biotechnology] industry ranges from $302.51B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GYRE’s FA Score shows that 1 FA rating(s) are green whilePYXS’s FA Score has 1 green FA rating(s).

  • GYRE’s FA Score: 1 green, 4 red.
  • PYXS’s FA Score: 1 green, 4 red.
According to our system of comparison, both GYRE and PYXS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GYRE’s TA Score shows that 4 TA indicator(s) are bullish while PYXS’s TA Score has 5 bullish TA indicator(s).

  • GYRE’s TA Score: 4 bullish, 5 bearish.
  • PYXS’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, PYXS is a better buy in the short-term than GYRE.

Price Growth

GYRE (@Biotechnology) experienced а -16.18% price change this week, while PYXS (@Biotechnology) price change was -18.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -9.07%. For the same industry, the average monthly price growth was -13.26%, and the average quarterly price growth was -12.25%.

Reported Earning Dates

GYRE is expected to report earnings on May 08, 2025.

PYXS is expected to report earnings on May 09, 2025.

Industries' Descriptions

@Biotechnology (-9.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GYRE($600M) has a higher market cap than PYXS($60.7M). GYRE (-36.198) and PYXS (-37.186) have similar YTD gains . GYRE has higher annual earnings (EBITDA): 11.8M vs. PYXS (-64.04M). PYXS has more cash in the bank: 145M vs. GYRE (25.1M). GYRE has less debt than PYXS: GYRE (1.8M) vs PYXS (20.5M). GYRE has higher revenues than PYXS: GYRE (105M) vs PYXS (16.1M).
GYREPYXSGYRE / PYXS
Capitalization600M60.7M988%
EBITDA11.8M-64.04M-18%
Gain YTD-36.198-37.18697%
P/E Ratio154.20N/A-
Revenue105M16.1M652%
Total Cash25.1M145M17%
Total Debt1.8M20.5M9%
FUNDAMENTALS RATINGS
GYRE: Fundamental Ratings
GYRE
OUTLOOK RATING
1..100
68
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
PROFIT vs RISK RATING
1..100
89
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
89
P/E GROWTH RATING
1..100
4
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GYREPYXS
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
74%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 5 days ago
82%
Bullish Trend 12 days ago
80%
Declines
ODDS (%)
Bearish Trend 9 days ago
82%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 5 days ago
90%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PYXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HURN143.451.15
+0.81%
Huron Consulting Group
CAT329.800.11
+0.03%
Caterpillar
CGNX29.83-0.18
-0.60%
Cognex Corp
FARO27.30-0.19
-0.67%
FARO Technologies
ACRV2.03-0.21
-9.38%
Acrivon Therapeutics

GYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GYRE has been loosely correlated with SPRC. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if GYRE jumps, then SPRC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GYRE
1D Price
Change %
GYRE100%
-15.26%
SPRC - GYRE
38%
Loosely correlated
-5.78%
SRPT - GYRE
33%
Loosely correlated
-9.36%
AURA - GYRE
33%
Poorly correlated
-7.57%
RYTM - GYRE
32%
Poorly correlated
-3.34%
KYMR - GYRE
32%
Poorly correlated
-7.60%
More

PYXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, PYXS has been loosely correlated with KURA. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if PYXS jumps, then KURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PYXS
1D Price
Change %
PYXS100%
-7.56%
KURA - PYXS
64%
Loosely correlated
-6.38%
CTMX - PYXS
39%
Loosely correlated
+1.21%
ABOS - PYXS
37%
Loosely correlated
-7.56%
BLRX - PYXS
37%
Loosely correlated
-2.95%
RXRX - PYXS
34%
Loosely correlated
-8.95%
More